scholarly article | Q13442814 |
P50 | author | Guillermo Ruiz-Irastorza | Q37830875 |
Andrea Doria | Q38544117 | ||
David A. Isenberg | Q42326409 | ||
Gabriella Szűcs | Q91312009 | ||
Xavier Mariette | Q93104907 | ||
Manuel Ramos-casals | Q42646201 | ||
Ronald van Vollenhoven | Q47265013 | ||
Elisa Gremese | Q50166371 | ||
Tom Huizinga | Q77086497 | ||
P2093 | author name string | Thomas Dörner | |
Ola Nived | |||
Cristina Gonzalez-Echavarri | |||
Marta Mosca | |||
Murat Inanç | |||
Søren Jacobsen | |||
Joaquim Oristrell | |||
Antoni Castro | |||
Monica Rydén-Aulin | |||
Gian Domenico Sebastiani | |||
Dimitrios Boumpas | |||
Jose Luis Callejas Rubio | |||
Luis Caminal-Montero | |||
Annamaria Iuliano | |||
Luis Sáez-Comet | |||
Lászlo Kovács | |||
Danilo Squatrito | |||
Frederic A Houssiau | |||
Alexandre Voskuyl | |||
Javier Rascón | |||
Agustín Colodro Ruiz | |||
Gonzalo Salvador Cervelló | |||
Irene Bultink | |||
Juan Jimenéz-Alonso | |||
P2860 | cites work | A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus | Q28254310 |
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. | Q30967810 | ||
Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. | Q33491307 | ||
The prevalence of rheumatic diseases in central Greece: a population survey | Q33588016 | ||
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases | Q34369159 | ||
Rituximab versus cyclophosphamide for ANCA-associated vasculitis | Q35109118 | ||
British Society for Rheumatology Biologics Register | Q35579314 | ||
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial | Q35993027 | ||
Rheumatoid arthritis registries in Sweden. | Q36307644 | ||
Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy | Q36518986 | ||
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome | Q37123206 | ||
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. | Q38205079 | ||
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study | Q38466691 | ||
Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001. | Q39645963 | ||
Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy | Q40331569 | ||
The prevalences of some rheumatic diseases in western Turkey: Havsa study | Q40337416 | ||
Prolonged remission in Caucasian patients with SLE: prevalence and outcomes | Q41533364 | ||
Lupus in Germany: analysis within the German lupus self-help organization (LULA) | Q41912513 | ||
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis | Q80060133 | ||
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab | Q80502406 | ||
Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases | Q81963943 | ||
Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER) | Q83817360 | ||
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis | Q42963758 | ||
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. | Q43472878 | ||
An open study of B lymphocyte depletion in systemic lupus erythematosus | Q44183280 | ||
Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms; the high prevalence in black women | Q44531096 | ||
Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality | Q44795825 | ||
The prevalence of systemic lupus erythematosus in Northern Ireland | Q44940491 | ||
Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? | Q45991822 | ||
Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study | Q46140763 | ||
Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features | Q47329844 | ||
An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life | Q48435382 | ||
DANBIO: a nationwide registry of biological therapies in Denmark. | Q50542827 | ||
Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort. | Q50561696 | ||
Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. | Q50658322 | ||
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). | Q51201612 | ||
The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. | Q51967849 | ||
Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response | Q57349317 | ||
The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990 | Q60704939 | ||
Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy | Q61628464 | ||
The prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester city, UK | Q67551750 | ||
The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth | Q72158504 | ||
P433 | issue | 1 | |
P921 | main subject | systemic lupus erythematosus | Q1485 |
rituximab | Q412323 | ||
P304 | page(s) | e000163 | |
P577 | publication date | 2016-09-06 | |
P1433 | published in | Lupus science & medicine | Q27725658 |
P1476 | title | Off-label use of rituximab for systemic lupus erythematosus in Europe | |
P478 | volume | 3 |
Q47660691 | B Cell-Based Treatments in SLE: Past Experience and Current Directions |
Q92987312 | B cell checkpoints in autoimmune rheumatic diseases |
Q40042816 | Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome |
Q42373160 | Current perspective on rituximab in rheumatic diseases |
Q64065293 | Immunosuppressive therapy with rituximab in common variable immunodeficiency |
Q92540366 | Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus |
Q92625516 | Novel paradigms in systemic lupus erythematosus |
Q92481861 | Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card |
Q33811635 | Systemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE. |
Q33665611 | The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries |
Q42372842 | Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? |
Q90614367 | [Biologicals and small molecules for systemic lupus erythematosus] |
Q89894663 | [Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus] |
Search more.